Swiss biotech CSO/CMO meeting
Wednesday, September 2, 2026, 9:30 - 17:30 and evening reception
Fondation ISREC, Bâtiment AGORA, Rue du Bugnon 25A, 1005 Lausanne
We are delighted to invite you to our first informal peer-to-peer meeting for chief scientific and chief medical officers.
Join us for a program designed to guide you through the critical stages of drug development. Experienced scientific and medical leaders share practical insights, real-world lessons, and actionable strategies across both non-clinical and clinical development phases in an informal setting.
Through expert talks and interactive discussions, the meeting fosters collaboration and strengthens excellence across the Swiss biotech ecosystem.
Help shape a relevant and impactful program—share your input during registration.
Know a CSO/CMO who should join?
Please share the contact details of any CSO/CMO peers (full name, organization, email, function) whom you believe we should also invite. Alternatively, you may forward the invitation to them directly. If your organization does not have a dedicated CSO/CMO, you are kindly invited to register yourself.
Join us at the SITC EU Immuno-Oncology Drug Development Summit
After the CSO/CMO meeting, continue at the SITC EU Immuno-Oncology Drug Development Summit at the same venue on September 3, 2026. All CSO/CMO meeting participants, as well as Swiss Biotech Association members benefit from a 10% discount.
Kindly supported by
Program
9:30
Welcome note
- Madiha Derouazi, Swiss Biotech Association board member & CEO, SwitchKine
- Michael Altorfer, CEO, Swiss Biotech Association
- François Capel, Innovation Advisor, Innovaud
9:45
From leads to development – Biologics
- Jonathan Kearsey, Co-founder & Managing Director, Leads To Development
10:15
From leads to development – Small molecules
- Marc Ceusters, Head of Development, Switchkine
10:45
Experience from a drug hunter
- Martine Clozel, CSO, Idorsia
11:15
Panel with Chief Scientific Officers on key learnings and common pitfalls
Moderated by Michael Stumpp, EVP Molecular Partners
- Martine Clozel, CSO, Idorsia
- Davide Corti, SVP Antibody Research, Vir Biotechnology
- Frédéric Levy, CSO, Head of external & internal innovation, Debiopharm
- Nadège Pelletier, CSO, Aluma Therapeutics
- Martin Steegmaier, CSO, Molecular Partners
12:30
Networking lunch
13:30
In vivo activities and toxicology studies: Key learnings
- Susana Salgado Pires, Non-Clinical Advisor, Novartis
14:15
Regulatory framework in Switzerland and scientific advice for clinical trials phase 1
- Rolf Kaiser, Swissmedic
15:00
Coffee break
15:30
Trends for clinical trials: Designs, geographies, pitfalls
- Dominik Hartl, CMO – Drug Development Immunology, Granite Bio
16:30
Roundtable with Chief Medical Officers on key learnings and common pitfalls
Moderated by Philippe Legenne, CMO, Molecular Partners
- Dominik Hartl, CMO – Drug Development Immunology, Granite Bio
- Shabir Hasham, CMO, Santhera Pharmaceuticals
- Amer Joseph, CMO, Idorsia
- Rolf Kaiser, Swissmedic
- Michael Lahn, CMO, iOnctura